Jiangnan University

Zhen Wang

Yongquan Chen

Shenglong Zhu

The disclosure discloses an anti-metabolic disorder FGF analog and an application thereof, and belongs to the technical field of medicines. According to the disclosure, modification is performed based on an FGF19 mutant NGM282 to obtain a FGF19 analog, and the FGF19 analog is used in treating liver impairment, metabolic disorders, obesity, overweight, metabolic syndrome, diabetes and dyslipidemia and has no side effects of elevated cholesterol and dietary decline in a therapeutic process.

FGF analog

The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.

Growing community of inventors

Wuxi, China

Zhen Wang